News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
235 Results
Type
Article (2)
Company Profile (1)
Press Release (232)
Section
Business (39)
Drug Development (33)
FDA (28)
Job Trends (5)
News (108)
Policy (12)
Tag
Academia (1)
Alliances (13)
Approvals (31)
Best Places to Work (5)
Cardiovascular disease (5)
Clinical research (35)
Data (7)
Diabetes (3)
Drug pricing (1)
Earnings (7)
Events (19)
FDA (33)
GLP-1 (4)
Healthcare (21)
Indications (2)
Job creations (3)
Legal (3)
Metabolic disorders (7)
NextGen: Class of 2026 (1)
Obesity (5)
People (13)
Pharmaceutical (1)
Phase 2 (5)
Phase 3 (26)
Pipeline (10)
Postmarket research (5)
Real estate (4)
Regulatory (14)
Weight loss (2)
Women's health (1)
Date
Last 7 days (1)
Last 30 days (2)
Last 365 days (12)
2026 (4)
2025 (11)
2024 (10)
2023 (5)
2022 (1)
2021 (8)
2020 (11)
2019 (15)
2018 (8)
2017 (15)
2016 (27)
2015 (6)
2014 (16)
2013 (17)
2012 (13)
2011 (12)
2010 (23)
Location
Europe (15)
New Jersey (21)
New York (1)
United States (22)
235 Results for "NovoNordiskUS".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access
February 24, 2026
·
15 min read
Press Releases
Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026
April 2, 2026
·
10 min read
Press Releases
FDA approves Novo Nordisk’s new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
March 19, 2026
·
14 min read
Press Releases
FDA approves Novo Nordisk’s Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications
March 2, 2026
·
13 min read
Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.
Business
Novo Nordisk to present new data from key diabetes and obesity trials at the 60th Annual Meeting of the European Association for the Study of Diabetes
September 6, 2024
·
5 min read
Press Releases
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
December 19, 2025
·
9 min read
Press Releases
Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
November 27, 2025
·
6 min read
Press Releases
Novo Nordisk’s CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
November 7, 2025
·
8 min read
Press Releases
Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
November 6, 2025
·
12 min read
1 of 24
Next
